📊 Get daily AI-graded market briefings
Morning + evening · AI impact + sector exposure · Free
LAST 30 DAYS
5 articles
AVG GRADE
NEUTRAL
score: 0.00
SENTIMENT
BULLISH
TOTAL VIEWS
2
4-DAY GRADE TIMELINE
2026-06-11
TODAY
RECENT COVERAGE · 15 ARTICLES
Eli Lilly, Regeneron among first companies selected for FDA initiative to speed review of new manufacturing facilities
Eli Lilly (LLY) and Regeneron (REGN) have secured early entry into the FDA's PreCheck Pilot Program, a regulatory initiative designed to...
Eli Lilly and Company (LLY) Up More Than 6% Over the Past Month, Can it Move Higher?
Eli Lilly (LLY) has demonstrated positive momentum with a 6% monthly gain, supported by analyst upgrades and consensus price targets...
Lilly, J&J, AbbVie hit all-time highs (LLY:NYSE)
Three large-cap Health Care names—Eli Lilly (LLY), Johnson & Johnson (JNJ), and AbbVie (ABBV)—have reached new 52-week highs, signaling...
Why breakthrough GLP-1 weight loss pills may be a bad thing for employer insurance coverage
The rapid adoption of GLP-1 weight-loss medications from Novo Nordisk and Eli Lilly presents a fundamental coverage disconnect between...
Obesity drugs approach a major milestone, and Lilly may have a 'game changer' ahead
Eli Lilly (LLY) appears positioned for a significant catalyst event tied to obesity drug advancement. The reference to an imminent "game...
Lilly launches cancer therapy drug Tanstrive
Eli Lilly (LLY) has launched Tanstrive, a targeted oral cancer therapy designed for RET-altered tumors, marking another expansion in its...
Tanstrive cost, dosage: Eli Lilly launches cancer drug in India, priced at ₹2.15 lakh per box
Eli Lilly has expanded its oncology portfolio into the Indian market through the launch of Tanstrive, a cancer therapeutic priced at...
Eli Lilly and Company (LLY) – Among the 10 Reliable Dividend Stocks to Buy for Long-Term Investors
Eli Lilly (LLY) has signaled a material expansion of its weight-loss pharmaceutical portfolio into European markets, with European Union...
Absci: Eli Lilly Backs Alopecia Data With Funding, But Risks Remain (NASDAQ:ABSI)
ABSI rallied 30% on the back of a $100M equity investment from pharmaceutical heavyweight Eli Lilly, signaling institutional validation...
Abbisko Therapeutics Deepens R&D Collaboration with Lilly
Eli Lilly and Company (LLY) has formalized a strategic research collaboration with Abbisko Therapeutics, a Hong Kong-listed biotech...
Eli Lilly vs Viking Therapeutics: Which GLP-1 Stock Is the Better Buy?
The GLP-1 pharmaceutical market continues to demonstrate robust secular growth tailwinds, with both Eli Lilly (LLY) and Viking...
Sangamo Therapeutics Enters Into Asset Sale Agreements with Lilly and Astellas
Sangamo Therapeutics (SGMO) has entered into asset sale agreements with Eli Lilly (LLY) and Astellas Pharma as part of a voluntary...
Acquisition of Centessa by Lilly Approved by the High Court of Justice of England and Wales
Eli Lilly's (LLY) acquisition of Centessa Pharmaceuticals (CNTA) has cleared a major regulatory hurdle with High Court approval in...
Acquisition of Centessa by Lilly Approved by the High Court of Justice of England and Wales
Eli Lilly's acquisition of Centessa Pharmaceuticals has received final regulatory clearance from the UK High Court, removing the last...
Is Eli Lilly and Company (LLY) among the Best Longevity and Anti-Aging Stocks to Buy?
Eli Lilly (LLY) has been identified among a curated list of longevity and anti-aging stocks, reflecting sustained institutional interest...
RELATED TICKERS
E
ESEN Analytics
AI-powered equity research platform covering 5,000+ US equities. Our proprietary AI grading system (A+ to D scale) analyzes fundamentals, technicals, and news sentiment daily. Coverage data updated every 24 hours.
Learn about our methodology →
ⓘ AI-graded news coverage · Not investment advice